Barbara Dalton

Barbara Dalton is Senior Managing Partner, at Pfizer Ventures and Vice President, Worldwide Business Development at Pfizer. She has led Pfizer Ventures since joining Pfizer in 2007. The Pfizer Ventures team has invested in over 110 companies and approximately 20 funds, pursuing products, technologies, and services, relevant to all aspects of Pfizer's business. Barbara has overall responsibility for Pfizer Ventures and directly manages investments in all funds and in the portfolio companies AMRA, Artios, Cydan, Imara, Ixchelsis, Levicept, Ravenna, Resilience, Saama, Second Genome, and Simcha. She also chairs the Healthcare Advisory Board of the Partnership Fund for NYC.

Barbara's pharmaceutical career started in the Immunology Division of Smith Kline & French Research Laboratories. She moved to venture to invest in 1993 when she joined their venture capital group, S.R. One, Limited. In 2000 Barbara became a General Partner in EuclidSR Partners, the private venture fund that was supported by GSK (then SB) as a sister fund to S.R. One, Limited.

Barbara received her undergraduate degree from Penn State and her Ph.D. in Immunology and Microbiology from the Medical College of Pennsylvania (now Drexel University School of Medicine).